Latest Curis Inc (CRIS) Headlines Curis to Present at

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Latest Curis Inc (CRIS) Headlines

Curis to Present at the 26th Annual ROTH Conference
GlobeNewswire - Tue Mar 04, 6:11AM CST
Curis, Inc. (Nasdaq:CRIS), an oncology-focused company developing novel, targeted drug candidates for the treatment of human cancers, today announced that the Company will present at the 26 Annual ROTH Conference at 8:30 a.m. PT on March 11, 2014, in Laguna Niguel, CA.

Narrower-than-Expected Loss at Curis - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Feb 26, 12:30PM CST
Curis reported fourth quarter 2013 net loss per share of 5 cents, narrower than the Zacks Consensus Estimate of a loss of 7 cents.

Curis to Present at the Cowen and Company 34th Annual Health Care Conference
GlobeNewswire - Tue Feb 25, 6:14AM CST
Curis, Inc. (Nasdaq:CRIS), an oncology-focused company developing novel, targeted drug candidates for the treatment of human cancers, today announced that the Company will present at the Cowen and Company 34 Annual Health Care Conference at 4:50 p.m. ET on March 3, 2014, in Boston.

Small Business Owners Heading Into Retirement May Be Underestimating Value of Their Business: Scotiabank Study
Marketwire Canada - Tue Feb 25, 5:30AM CST
According to a recent Scotiabank poll, a quarter of Canada's small business owners (26%) expect their RRSP contributions to be their primary source of income in retirement, followed by proceeds from selling their business (17%), their savings (15%) and government pensions (8%).

Stock to Watch: Curis Up 5.4% (CRIS)
Comtex SmarTrend(R) - Thu Feb 20, 12:46PM CST
Curis (NASDAQ:CRIS) is one of today's best performing low-priced stocks, up 5.4% to $3.13 on 1.2x average daily volume. Thus far today, Curis has traded 564,000 shares, vs. average volume of 484,000 shares per day. The stock has outperformed the Dow (5.4% to the Dow's 0.7%) and outperformed the S&P 500 (5.4% to the S&P's 0.6%) during today's trading.

Curis Reports Fourth Quarter and Year-End 2013 Financial Results
GlobeNewswire - Thu Feb 20, 6:00AM CST
Curis, Inc. (Nasdaq:CRIS), an oncology-focused company developing novel, targeted drug candidates for the treatment of human cancers, today reported its financial results for the fourth quarter and year ended December 31, 2013.

Curis to Present at the RBC Capital Markets Global Healthcare Conference
GlobeNewswire - Wed Feb 19, 3:15PM CST
Curis, Inc. (Nasdaq:CRIS), an oncology-focused drug development company seeking to develop novel drug candidates for the treatment of human cancers, today announced that the Company will present at the RBC Capital Markets Global Healthcare Conference at 1:35 p.m. ET on February 26, 2014, in New York City.

Curis to Release Fourth Quarter and Year End 2013 Financial Results and Hold Conference Call on February 20, 2014
GlobeNewswire - Thu Feb 13, 6:00AM CST
Curis, Inc. (Nasdaq:CRIS), an oncology focused company developing novel, targeted drug candidates for the treatment of human cancers, today announced that the Company will release its fourth quarter and year-end 2013 financial results on Thursday, February 20, 2014, before the market opens. The Company's management will also host a conference call on the same day at 9:00 A.M. Eastern Standard Time to provide an overview of its proprietary clinical development programs, including CUDC-907 and CUDC-427 as well as its partnered programs, including Erivedge(R) (vismodegib) and Debio 0932. The Company's management will also review its financial results as of and for the fourth quarter and year ended December 31, 2013.

Curis to Present at the Leerink Global Healthcare Conference
GlobeNewswire - Wed Feb 05, 6:00AM CST
Curis, Inc. (Nasdaq:CRIS), an oncology-focused drug development company seeking to develop novel drug candidates for the treatment of human cancers, today announced that the Company will present at the Leerink Global Healthcare Conference at 10:40 a.m. ET on February 12, 2014, in New York City.

4 Stocks Under $10 Making Big Moves
at The Street - Fri Dec 20, 7:53AM CST
When a stock makes a large-percentage move, it is often just the start of a new major trend -- a trend that can lead to huge profits.

This Week in Biotech
Sean Williams, The Motley Fool - Motley Fool - Sat Dec 14, 11:05AM CST
With the  SPDR S&P Biotech Index  up 38% over the trailing-12-month period, it's evident that investment dollars are willingly flowing into the biotech sector. Keeping that in mind, let's have a look at some of the rulings, studies, and companies...

Why Curis Inc. Shares Tanked
Sean Williams, The Motley Fool - Motley Fool - Mon Dec 09, 4:44PM CST
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. What: Shares of Curis , a clinical-stage biopharmaceutical...

Curis Down 14.0%, Shares Slide into the Red (CRIS)
Comtex SmarTrend(R) - Mon Dec 09, 11:42AM CST
Curis (NASDAQ:CRIS) is one of today's worst performing low-priced stocks, down 14.0% to $2.95 on 1.7x average daily volume. Thus far today, Curis has traded 1.2 million shares, vs. average volume of 659,000 shares per day. The stock has underperformed the Dow (-14.0% to the Dow's 0.1%) and underperformed the S&P 500 (-14.0% to the S&P's 0.3%) during today's trading.

Curis Reports CUDC-907 Preliminary Data From the Ongoing Phase 1 Trial at ASH 2013 Annual Meeting
GlobeNewswire - Mon Dec 09, 10:00AM CST
CUDC-907 (HDAC and PI3K inhibitor) demonstrates preliminary evidence of clinical activity

Global Stem Cell Anticancer Therapeutics Market Forecasts Report to 2016
M2 - Fri Dec 06, 6:16AM CST
Research and Markets (http://www.researchandmarkets.com/research/b9dnj7/global_stem_cell) has announced the addition of the "Global Stem Cell Anticancer Therapeutics Market Forecasts Report to 2016" report to their offering. One of the main factors driving the market is the significant increase in the drug pipeline targeting cancer stem cells. These cells have the capacity to divide and give rise to new cancer stem cells through a process called self-renewal and have the ability to change into the other cells that form the bulk of the tumour. One of the main trends witnessed in the Global Stem Cell Anticancer Therapeutics market is the increase in industry activities. Cancer therapy apart from usual radiotherapy has entered into new era of stem cell therapy. Research is going on to recognize and isolate cancer stem cells with those of normal stem cells by using cell surface antigen markers. More intricate research work is needed to carry out reveal signalling pathways and functioning of different genes in process of carcinogenesis during cancer stem cell differentiation. This would help in development of new therapies which would help in elimination of eventual disease and recurrence. This trend is expected to have a strong impact on the growth of the market. Further, the report states that one of the main challenges is the lack of awareness in developing countries. Most of the patients in developing countries such as India and China are not fully aware of the recent developments in stem cell products and therapies. The key vendors dominating this space include: - Celgene Corp. - Curis Inc. - Exelixis Inc. - Gamida Cell Ltd. - Lonza Group - Merck & Co. Inc. - OncoMed Pharmaceuticals Inc. - Pfizer Inc. - Roche Holding AG - Teva Pharmaceutical Industries Ltd. - Verastem Inc. Key Topics Covered: 01. Executive Summary 02. List of Abbreviations 03. Introduction 04. Market Research Methodology 05. Scope of the Report 06. Stem Cells 07. Market Landscape 08. Geographical Segmentation 09. Vendor Landscape 10. Buying Criteria 11. Market Growth Drivers 12. Drivers and their Impact 13. Market Challenges 14. Impact of Drivers and Challenges 15. Market Trends 16. Key Vendor Analysis For more information visit http://www.researchandmarkets.com/research/b9..._stem_cell

Curis to Present at the Oppenheimer 24th Annual Healthcare Conference
GlobeNewswire - Wed Dec 04, 6:00AM CST
Curis, Inc. (Nasdaq:CRIS), an oncology-focused drug development company seeking to develop novel drug candidates for the treatment of human cancers, today announced that the Company will present at the Oppenheimer 24 Annual Healthcare Conference at 2:45 p.m. ET on December 11, 2013, in New York City.

Curis, Inc. (CRIS) Soars: Stock Adds 11.7% in Session - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Nov 26, 6:51AM CST
Curis, Inc. was a big mover last session as its shares surged around 12% on the day.

Curis to Present at Upcoming Investor Conferences
GlobeNewswire - Tue Nov 26, 6:00AM CST
Curis, Inc. (Nasdaq:CRIS), an oncology-focused drug development company seeking to develop novel drug candidates for the treatment of human cancers, today announced that the Company will present at the following upcoming conferences:

Traders Get Bullish on Shares of Curis, Shares Up 8.9% (CRIS)
Comtex SmarTrend(R) - Mon Nov 25, 11:45AM CST
Curis (NASDAQ:CRIS) is one of today's best performing low-priced stocks, up 8.9% to $3.07 on 1.0x average daily volume. Thus far today, Curis has traded 641,000 shares, vs. average volume of 628,000 shares per day. The stock has outperformed the Dow (8.9% to the Dow's 0.2%) and outperformed the S&P 500 (8.9% to the S&P's 0.1%) during today's trading.

Curis Inc. (CRIS) Stock Research Links

CRIS Board Company Profile Buy Rating Time & Sales News Filings Financials
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Early Therapy After Sports Injuries Deserves Careful Timing

Updated Category News Views 80

A limp can become a bad habit long before an athlete calls it one. That is the plain, useful concern behind Dr. Kali Spoto LaRue's discussion of sports-injury physical therapy for athletes in Fairport and Greater Rochester. The central message is not that every sore muscle needs the same response, nor that anybody should charge back into practice because they had one...

Continue Reading
SDG&E's 21-Year Reliability Run Has Real Investor Weight

Updated Category News Views 56

Seventy minutes without power in a year is the sort of number most people ignore until their refrigerator quits humming. For San Diego Gas & Electric customers, though, it is a meaningful operating result: roughly 70 minutes annually from unplanned outages, on average, over the past decade, alongside fewer than one sustained outage per customer each year. SDG&E has also...

Continue Reading
Robert Half's Parent Support Earns Fortune Recognition

Updated Category News Views 114

A workplace award rarely moves a staffing stock by itself, and it shouldn’t. Still, Fortune naming Robert Half among its Best Workplaces for Parents for 2026 is more than decorative corporate wallpaper. In the talent business, the company’s own ability to recruit, retain and support people is part of the product. Clients hire Robert Half because they need skilled...

Continue Reading
Why Professional Collaboration May Matter More in AI

Updated Category News Views 51

Three smart professionals can still hand a client a mess when nobody owns the handoff. That unglamorous reality sits behind the Professional Collaboration Institute, or PCI, which Sarano and Brooke Kelley plan to launch in a virtual briefing on December 2. The outfit wants to turn cross-profession coordination into a teachable, measurable discipline rather than leave it...

Continue Reading
First Grade Literacy Push Deserves a Harder Look Now

Updated Category News Views 146

A reading gap can become a concrete wall before anyone bothers measuring it. That is the uncomfortable point behind Ignite Reading's First Grade Promise, and it deserves more attention than another polished education announcement usually gets. At a Nov. 5 Convene 2026 gathering in Boston, 56 district and literacy leaders from six states focused on getting children reading...

Continue Reading
Alphabet Lawsuit Puts Gemini Delays Under a Microscope

Updated Category News Views 189

July’s twin punches to Alphabet shares were not the sort of wobble investors can casually shrug off. First came a report on July 16 that Google was months behind on Gemini 3.5 Pro, its flagship AI model, after disappointing results from updated training data. Then came the harder financial reality a week later: a much larger 2026 capital-spending plan, negative...

Continue Reading
Home Nursing Plans Need Clarity Before the Next Crisis

Updated Category News Views 16

A medication change scribbled on a loose sheet can become a very long night. That is the unglamorous truth behind the discussion from Michael and Marsha Reda of Aurora Home Care in Williamsville, New York: long-term home nursing care depends on a plan people can actually follow when the household is tired, worried, and juggling too much. Their perspective, featured by...

Continue Reading
Carnival Maps a Longer, Broader Bet on Cruise Demand

Updated Category News Views 36

A cruise operator does not order ships for 2035 because it is feeling timid. Carnival is laying out a long runway of hardware, private-destination capacity and onboard-to-onshore spending hooks, all aimed at keeping guests inside its ecosystem longer. For NYSE:CCL, this is not a next-quarter story. It is a very public statement that management sees enduring appetite for...

Continue Reading
Specialized Metal Makers Become the New M&A Prize Again

Updated Category News Views 44

A forgotten heat-treatment line can suddenly be worth more than a shiny new mill when buyers realize nobody can duplicate its certifications, workforce, and customer approvals overnight. That is the basic truth sitting underneath BGL's Nov. 19, 2026 assessment of the U.S. metals market. The easy headline is consolidation. The useful takeaway is much narrower: specialized...

Continue Reading
PPL's January Dividend Keeps Utility Appeal Intact

Updated Category News Views 17

A dividend notice is rarely thrilling, but it can still separate a steady utility from a story stock peddling fumes. PPL Corporation declared a quarterly common dividend of $0.2850 per share on Nov. 20, payable Jan. 4, 2027. Shareholders must be on the books by Dec. 10, 2026, to receive it. Plain vanilla stuff, yes. Still, plain vanilla is often precisely why utility...

Continue Reading

Top 5 Most Recently Viewed Articles

Exploring the Expanding Scope of Implantable Medical Devices

Updated Category News Views 122

Overview of the Implantable Medical Devices Market The global market for implantable medical devices is witnessing remarkable growth, with projections estimating it to reach approximately USD 176.33 billion by 2034, escalating at a compound annual growth rate (CAGR) of 6.14%. This rise is largely influenced by a steadily increasing prevalence of chronic diseases and an...

Continue Reading
Revolutionizing Home Financing: The Launch of Rate Intelligence

Updated Category News Views 109

Rate's Innovative AI Solution for Mortgage Lending Rate, a pioneer in financial technology, has recently introduced Rate Intelligence—an advanced AI platform that seeks to redefine the mortgage experience for both homebuyers and loan officers. By leveraging cutting-edge technology, Rate is on a mission to enhance efficiency, speed, and accuracy in the home financing...

Continue Reading
Lindahl Reed Secures OASIS+ Contracts to Enhance Services

Updated Category News Views 163

Lindahl Reed Achieves Significant OASIS+ Contract Awards Lindahl Reed, Inc., a prominent player in the technical and scientific services arena, has recently been awarded the One Acquisition Solution for Integrated Services Plus (OASIS+) – 8(a) and Women-Owned Small Business (WOSB) Multi-Agency Contract master contracts. This new development is noteworthy as it allows...

Continue Reading
Safe Bulkers (NYSE: SB) Sees 52-Week Low Amid Market Struggles

Updated Category News Views 334

Safe Bulkers (NYSE: SB) Faces Market Challenges In a challenging environment for investors, Safe Bulkers Inc. (NYSE: SB) has witnessed its stock drop to a 52-week low, currently standing at $3.4. This decline highlights the broader issues prevalent in the shipping sector, where shifts in demand and fluctuating shipping rates have placed pressure on many companies,...

Continue Reading
Emerging Cybersecurity Trends for 2026: AI's Dual Role

Updated Category News Views 280

Understanding 2026: Cybersecurity Predictions and Insights In an era where technology is evolving at a rapid pace, organizations find themselves at a critical juncture. The proliferation of AI poses both unprecedented opportunities and significant threats. Businesses must stay vigilant against a historic wave of DNS exploitation alongside an evolving threat landscape. As...

Continue Reading